00:39 , Nov 20, 2018 |  BC Extra  |  Clinical News

Aimmune down on safety concerns for peanut allergy therapy

Aimmune Therapeutics Inc. (NASDAQ:AIMT) was off $3.33 (11%) to $26.29 on Monday after the...
19:59 , Nov 16, 2018 |  BioCentury  |  Tools & Techniques

Benchtop manufacturing gets smaller

Publisher’s note: This story originally ran in the Nov. 15, 2018 issue of...
22:43 , Nov 15, 2018 |  BC Innovations  |  Tools & Techniques

Benchtop manufacturing gets smaller

MIT scientists continue to break new ground in benchtop manufacturing systems for biologics. Published in...
15:08 , Nov 15, 2018 |  BioCentury  |  Politics, Policy & Law

Requiring Drug Prices in TV Ads Violates First Amendment

Drug companies, which have learned to live with advertisements calling out a litany of possible side effects for their drugs, may want to take a couple of aspirin. The recent announcement by CMS that it...
01:43 , Nov 14, 2018 |  BC Extra  |  Politics & Policy

Biopharma may have to wait for Brexit details

With U.K. and EU governments reaching a draft Brexit deal on Tuesday, the future of drug regulation in the U.K. and the country’s participation in EU science programs may take months to hammer out even...
00:34 , Nov 3, 2018 |  BioCentury  |  Finance

Part B exposure

HHS Secretary Alex Azar's proposed changes to Medicare Part B have put at least four large biopharmas at risk of substantial U.S. revenue losses. But the lack of market reaction and the views of VCs...
03:23 , Oct 27, 2018 |  BioCentury  |  Politics, Policy & Law

Trump’s divide and conquer Part B plan

While its rollout was timed to provide Republicans with ammunition in the last-minute run to the mid-term elections, the Trump administration’s proposal to revamp Part B drug payments won’t go into effect until 2020, at...
23:44 , Oct 18, 2018 |  BC Innovations  |  Targets & Mechanisms

Volkow: why pain and addiction will go personalized

While addiction still carries a social stigma, neuroscience research not only supports the view that it is a disease, but is starting to paint a more nuanced picture of the variety of mechanistic pathways involved....
20:15 , Oct 4, 2018 |  BioCentury  |  Politics, Policy & Law

Research from Mars can fail patients from Venus

Despite rules and directives pushing for clinical trials to include proportional representation of both sexes, some researchers and developers are still behind the curve. FDA, BIO and nonprofit organizations are providing new tools and resources...
01:21 , Sep 21, 2018 |  BC Innovations  |  Tools & Techniques

Precision for pancreatic cancer

Real-time sequencing and organoid-based screens in pancreatic cancer could place new targets and biomarkers in the hands of drug developers looking for ways to side-step KRAS, a gene mutated in 90% of patients. Because KRAS...